Mammographic features of calcifications in DCIS: Correlation with oestrogen receptor and human epidermal growth factor receptor 2 status

European Radiology

Volumn 23, Issue 8, 2013, Pages 2072-2078

  Bae, Min Sun ^a   Moon, Woo Kyung ^a   Chang, Jung Min ^a   Cho, Nariya ^a   Park, So Yeon ^a   Won, Jae Kyung ^a   Jeon, Yoon Kyung ^a   Moon, Hyeong Gon ^a   Han, Wonshik ^a   Park, In Ae ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

Breast; Calcification; HER2*DCIS; Mammography

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN P53;

ADULT; AGED; ARTICLE; BREAST CANCER; CALCIFICATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MORPHOLOGY; PRIORITY JOURNAL; RADIOLOGIST; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BREAST NEOPLASMS; CALCINOSIS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAMMOGRAPHY; MIDDLE AGED; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES;

EID: 84880325912     PISSN: 09387994     EISSN: 14321084     Source Type: Journal    
DOI: 10.1007/s00330-013-2827-9     Document Type: Article

References (43)

1. Kerlikowske K (2010) Epidemiology of ductal carcinoma in situ. J Natl Cancer Inst Monogr 41:139-141
2. Allred DC (2010) Ductal carcinoma in situ: terminology, classification, and natural history. J Natl Cancer Inst Monogr 41:134-138
3. Burstein HK, Polyak K, Wong JS et al (2004) Ductal carcinoma in situ of the breast. N Engl J Med 350:1430-1441
4. Erbas B, Provenzano E, Armes J et al (2006) The natural history of ductal carcinoma in situ of the breast: a review. Breast Cancer Res Treat 97:135-144
5. D'Orsi CJ (2010) Imaging for the diagnosis and management of ductal carcinoma in situ. J Natl Cancer Inst Monogr 41:214-217
6. Holmes P, Lloyd J, Chervoneva I et al (2011) Prognostic markers and long-term outcomes in ductal carcinoma in situ of the breast treated with excision alone. Cancer 117:3650-3657
7. Han K, Nofech-Mozes S, Narod S et al (2012) Expression of HER2neu in ductal carcinoma in situ is associated with local recurrence. Clin Oncol (R Coll Radiol) 24:183-189
8. Shao W, Brown M (2012) Advances in estrogen receptor biology: prospects for improvements in targeted breast cancer therapy. Breast Cancer Res 6:39-52
9. Provenzano E, Hopper JL, Biles GG et al (2003) Biological markers that predict clinical recurrence in ductal carcinoma in situ of the breast. Eur J Cancer 39:622-630
10. Rubin I, Yarden Y (2001) The basic biology of HER2. Ann Oncol 12:S3-S8
11. Leonard GD, Swain SM (2004) Ductal carcinoma in situ, complexities and challenges. J Natl Cancer Inst 96:906-920
12. Polyak K (2010) Molecular markers for the diagnosis and management of ductal carcinoma in situ. J Natl Cancer Inst Monogr 41:210-213
13. Perou CM, Sorlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406:747-752
14. Weigel S, Decker T, Korsching E, Hungermann D, Böcker W, Heindel W (2010) Calcifications in digital mammographic screening: improvement of early detection of invasive breast cancers? Radiology 255:738-745
15. Holland R, Schuurmans Stekhoven JH, Hendriks JHCL, Vebeek ALM, Mravunac M (1990) Extent, distribution, and mammographic/histologic correlations of breast ductal carcinoma in situ. Lancet 335:519-522
16. Dershaw DD, Giess CS, McCormick B et al (1997) Patterns of mammographically detected calcifications after breast-conserving therapy associated with tumor recurrence. Cancer 79:1355-1361
17. Antonio AL, Crespi CM (2010) Predictors of interobserver agreement in breast imaging using the Breast Imaging Reporting and Data System. Breast Cancer Res Treat 120:539-546
18. Badra FA, Karamouzis MV, Ravazoula P et al (2006) Non-palpable breast carcinomas: correlation of mammographically detected malignant-appearing microcalcifications and epidermal growth factor receptor (EGFR) family expression. Cancer Lett 244:34-41
19. Karamouzis MV, Likaki-Karatza E, Ravazoula P et al (2002) Non-palpable breast carcinomas: correlation of mammographically detected malignant-appearing microcalcifications and molecular prognostic factors. Int J Cancer 102:86-90
20. Gajdos C, Tartter PI, Bleiweiss IJ et al (2002) Mammographic appearance of nonpalpable breast cancer reflects pathologic characteristics. Ann Surg 235:246-251
21. Seo BK, Pisano ED, Kuzimak CM et al (2006) Correlation of HER-2/neu overexpression with mammography and age distribution in primary breast carcinomas. Acad Radiol 13:1211-1218
22. Evans AJ, Pinder SE, Ellis IO et al (1994) Correlations between the mammographic features of ductal carcinoma in situ (DCIS) and C-erbB-2 oncogene expression. Clin Radiol 49:559-562
23. Wang Y, Ikeda DM, Narasimhan B et al (2008) Estrogen receptor-negative invasive breast cancer: imaging features of tumors with and without human epidermal growth factor receptor type 2 overexpression. Radiology 246:367-375
24. American College of Radiology (2003) Breast Imaging Reporting and Data System (BI-RADS) (4th edition): mammography. American College of Radiology, Reston
25. Ohlschlegel C, Zahel K, Kradolfer D et al (2011) HER2 genetic heterogeneity in breast carcinoma. J Clin Pathol 64:1112-1116
26. Wolff AC, Hammond ME, Schwartz JN et al (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118-145
27. Allred DC, Wu Y, Mao S et al (2008) Ductal carcinoma in situ and emergence of diversity during breast cancer evolution. Clin Cancer Res 14:370-378
28. Hannemann J, Velds A, Halfwerk JB, Kreike B, Peterse JL, van de Vijver MJ (2006) Classification of ductal carcinoma in situ by gene expression profiling. Breast Cancer Res 8:R61
29. Bent CK, Bassett LW, D'Orsi CJ, Sayre JW (2010) The positive predictive value of BI-RADS microcalcification descriptors and final assessment categories. AJR Am J Roentgenol 194:1378-1383
30. Wiechmann L, Kuerer HM (2008) The molecular journey from ductal carcinoma in situ to invasive breast cancer. Cancer 112:2130-2142
31. Tsikitis VL, Chung MA (2006) Biology of ductal carcinoma in situ classification based on biologic potential. Am J Clin Oncol 29:305-310
32. Evans A, Pinder S, Wilson R et al (1994) Ductal carcinoma in situ of the breast: correlation between mammographic and pathologic findings. AJR Am J Roentgenol 162:1307-1311
33. Dinkel HP, Gassel AM, Tschammler A (2000) Is the appearance of microcalcifications on mammography useful in predicting histological grade of malignancy in ductal cancer in situ? Br J Radiol 73:938-944
34. McCaskill-Stevens W (2010) National Institutes of Health state-of-the-science conference on the management and diagnosis of ductal carcinoma in situ: a call to action. J Natl Cancer Inst Monogr 2010:111-112
35. Wang SY, Shamliyan T, Virnig BA, Kane R (2011) Tumor characteristics as predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis. Breast Cancer Res Treat 127:1-14
36. Kerlikowske K, Molinaro AM, Gauthier ML et al (2010) Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. J Natl Cancer Inst 102:627-637
37. Rakovitch E, Nofech-Mozes S, Hanna W et al (2012) HER2/neu and Ki67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ. Br J Cancer 106:1160-1165
38. Allred DC, Anderson SJ, Paik S et al (2012) Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24. J Clin Oncol 30:1268-1273
39. Kane RL, Virnig BA, Shamliyan T et al (2010) The impact of surgery, radiation, and systemic treatment on outcomes in patients with ductal carcinoma in situ. J Natl Cancer Inst Monogr 41:130-133
40. Sharma A, Koldovsky U, Xu S et al (2012) HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ. Cancer 118:4354-4362
41. Tamimi RM, Baer HJ, Marotti J et al (2008) Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer. Breast Cancer Res 10:R67-R76
42. Kojima Y, Tsunoda H, Honda S et al (2011) Radiographic features for triple negative ductal carcinoma in situ of the breast. Breast Cancer 18:213-220
43. Yang WT, Dryden M, Broglio K et al (2008) Mammographic features of triple receptor-negative primary breast cancers in young premenopausal women. Breast Cancer Res Treat 111:405-410